Gaucher's ERT row heats up as Shire rejects Genzyme suit
This article was originally published in Scrip
Executive Summary
Genzyme says it will "aggressively" pursue its complaint that its rival Shire allegedly put out "misleading statements" in a press release about a head to head trial looking at the firms' competing enzyme replacement therapies for Gaucher's disease. Genzyme's comments came after Shire filed for the dismissal of the suit in a Massachusetts court because, as Shire told Scrip, "it was concerned that Genzyme was seeking to stifle both the company's legitimate communications to investors as well genuine discussion and exchange of scientific data."
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.